Key result
Clinical outcomes for dabigatran, rivaroxaban, and apixaban versus warfarin could not be determined because the provided text only describes the Optum Research Data Assets without including the actual study results.
Why the study?
Do non-vitamin K antagonist oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce stroke or systemic embolism and major bleeding compared to warfarin in patients with nonvalvular atrial fibrillation?
Observational
Do non-vitamin K antagonist oral anticoagulants (apixaban, dabigatran, rivaroxaban) reduce stroke or systemic embolism and major bleeding compared to warfarin in patients with nonvalvular atrial fibrillation?
In a real-world US cohort, apixaban was associated with lower risks of both stroke and major bleeding compared to warfarin, while dabigatran and rivaroxaban showed similar stroke risks to warfarin.
No takes yet. Share an insight, caveat, or question.
Apixaban was associated with lower stroke risk than warfarin in this cohort; leaves open confirmation versus other NOACs in broader populations.
Yao et al. (2016) conducted an observational in Nonvalvular Atrial Fibrillation. Dabigatran, Rivaroxaban, Apixaban vs. Warfarin was evaluated. Clinical outcomes for dabigatran, rivaroxaban, and apixaban versus warfarin could not be determined because the provided text only describes the Optum Research Data Assets without including the actual study results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: